Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04573478 · ClinicalTrials.gov registry record · Phase 3
Atrasentan in Patients With IgA Nephropathy
A Phase 3 study of Immunoglobulin A Nephropathy and IgA Nephropathy, sponsored by Chinook Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 404
- Enrollment target
- 20
- Study locations
NCT04573478 is a Phase 3 study of Immunoglobulin A Nephropathy and IgA Nephropathy that is active but no longer recruiting, run by Chinook Therapeutics. The registered enrollment target is 404 participants, above the 273-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (48% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT04573478, a Phase 3 study of Immunoglobulin A Nephropathy and IgA Nephropathy, is active but no longer recruiting, sponsored by Chinook Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 404 participants
- Enrollment target
- 20
- Study locations
Study Summary
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Atrasentan
Study Locations (20)
California
- Comprehensive Research Institute - Alhambra
- Kidney Disease Medical Group - Glendale
- Stanford University - Stanford
North Carolina
- Mountain Kidney and Hypertension Associates - Asheville
- Brookview Hills Research Associates, LLC - Winston-Salem
Pennsylvania
- Lehigh Valley Hospital - Bethlehem
- University of Pennsylvania - Philadelphia
Texas
- Liberty Research Center - Dallas
- El Paso Kidney Specialists - El Paso
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- University of Florida - Gainesville
Georgia
- GA Nephrology Associates - Lawrenceville
Illinois
- NANI Research, LLC - Hinsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2020-12-11 |
| Est. Completion | 2026-12-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04573478
The ClinicalTrials.gov registry entry for NCT04573478 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 404 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 273-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (48% higher). The listed sponsor is Chinook Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04573478 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04573478 about?
NCT04573478 is a clinical study titled "Atrasentan in Patients With IgA Nephropathy". The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
What is the current status of trial NCT04573478?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 404 participants. The study started on 2020-12-11. Estimated completion is 2026-12-18.
What conditions does trial NCT04573478 study?
This clinical trial studies the following conditions: Immunoglobulin A Nephropathy, IgA Nephropathy.
What interventions are being tested in trial NCT04573478?
The interventions under investigation include: Placebo (DRUG), Atrasentan (DRUG).
Who is sponsoring clinical trial NCT04573478?
This trial is sponsored by Chinook Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04573478 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunoglobulin A Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ravulizumab in Pediatric Participants With Primary IgAN
RECRUITING · Phase 3
-
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
RECRUITING · Phase 3
-
A Study of Zigakibart in Adults With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.